Sposób żywienia a rak jajnika
Streszczenie
Ocena sposobu żywienia pacjentów onkologicznych stanowi nadal niewielki wycinek prac publikowanych w zakresie onkologii. Występujące w trakcie leczenia chemioterapią zmiany w zakresie odczuwania smaku, zapalenie błony śluzowej jamy ustnej, awersja do wybranych produktów żywnościowych, nudności i wymioty, biegunki czy zaparcia wraz z towarzyszącym osłabieniem oraz bólem wpływają niekorzystnie na stan odżywienia pacjentek. Prowadzenie badań naukowych w zakresie oceny sposobu żywienia pacjentów w trakcie chemioterapii wymaga ujęcia w metodyce choćby czasu wykonywania takiej oceny względem podawania cytostatyków. Sugeruje się, że występujące zmiany masy ciała w zaawansowanym raku jajnika jako istotny czynnik prognostyczny, natomiast otwartym pytaniem pozostaje czy zmiany masy ciała w trakcie chemioterapii powinny być ujmowane wyłącznie jako wykładnik metaboliczny nowotworu i czy wprowadzenie interwencji żywieniowej zapobiegającej utracie masy ciała wpłynęłoby na wydłużenie przeżyć.
Słowa kluczowe: masa ciałaotyłośćniedowagachemioterapiadieta
Referencje
- Cogliano V. International Agency for Research on Cancer (IARC) 〈http://www.iarc.fr〉. Toxicologic Pathology. 2016; 34(4): 405–406.
- Bae HS, Hong JH, Ki KD, et al. The effect of body mass index on survival in advanced epithelial ovarian cancer. J Korean Med Sci. 2014; 29(6): 793–797.
- Fotopoulou C, Hall M, Cruickshank D, et al. British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol. 2017; 213: 123–139.
- Bandera EV, Kushi LH, Rodriguez-Rodriguez L. Nutritional factors in ovarian cancer survival. Nutr Cancer. 2009; 61(5): 580–586.
- Yang HS, Yoon C, Myung SK, et al. Effect of obesity on survival of women with epithelial ovarian cancer: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer. 2011; 21(9): 1525–1532.
- Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med. 2012; 9(4): e1001200.
- Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2012; 5(7): 901–910.
- Gupta D, Lis CG, Vashi PG, et al. Impact of improved nutritional status on survival in ovarian cancer. Support Care Cancer. 2010; 18(3): 373–381.
- Backes FJ, Nagel CI, Bussewitz E, et al. The impact of body weight on ovarian cancer outcomes. Int J Gynecol Cancer. 2011; 21(9): 1601–1605.
- Hess LM, Barakat R, Tian C, et al. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2007; 107(2): 260–265.
- Stephenson LE, Bebb DG, Reimer RA, et al. Physical activity and diet behaviour in colorectal cancer patients receiving chemotherapy: associations with quality of life. BMC Gastroenterol. 2009; 9: 60.
- Grant M, Kravits K. Symptoms and their impact on nutrition. Semin Oncol Nurs. 2000; 16(2): 113–121.
- Boltong A, Keast R. The influence of chemotherapy on taste perception and food hedonics: a systematic review. Cancer Treat Rev. 2012; 38(2): 152–163.
- Boltong A, Keast R, Aranda S. Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment. Support Care Cancer. 2012; 20(11): 2765–2774.
- Gupta D, Lis CG, Vashi PG, et al. Impact of improved nutritional status on survival in ovarian cancer. Support Care Cancer. 2010; 18(3): 373–381.
- Richardson G, Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract. 2007; 13(4): 181–198.
- Calixto-Lima L, Martins de Andrade E, Gomes AP, et al. Dietetic management in gastrointestinal complications from antimalignant chemotherapy. Nutr Hosp. 2012; 27(1): 65–75.
- Malihi Z, Kandiah M, Chan YM, et al. The effect of dietary intake changes on nutritional status in acute leukaemia patients after first induction chemotherapy. Eur J Cancer Care (Engl). 2015; 24(4): 542–552.
- Jordan K, Gralla R, Jahn F, et al. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol. 2014; 722: 197–202.
- Benson AlB, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004; 22(14): 2918–2926.
- Laky B, Janda M, Cleghorn G, et al. Comparison of different nutritional assessments and body-composition measurements in detecting malnutrition among gynecologic cancer patients. Am J Clin Nutr. 2008; 87(6): 1678–1685.
- Beck AM, Balknäs UN, Fürst P, et al. Council of Europe (the Committee of Experts on Nutrition, Food Safety and Consumer Health of the Partial Agreement in the Social and Public Health Field). Food and nutritional care in hospitals: how to prevent undernutrition--report and guidelines from the Council of Europe. Clin Nutr. 2001; 20(5): 455–460.
- Mardas M, Jamka M, Mądry R, et al. Dietary habits changes and quality of life in patients undergoing chemotherapy for epithelial ovarian cancer. Support Care Cancer. 2015; 23(4): 1015–1023.
- Mardas M, Mądry R, Stelmach-Mardas M. Dietary intake variability in the cycle of cytotoxic chemotherapy. Support Care Cancer. 2016; 24(6): 2619–2625.
- Mardas M, Madry R, Stelmach-Mardas M. Link between diet and chemotherapy related gastrointestinal side effects. Contemp Oncol (Pozn). 2017; 21(2): 162–167.
- Mardas M, Stelmach-Mardas M, Zalewski K, et al. Influence of body weight changes on survival in patients undergoing chemotherapy for epithelial ovarian cancer. Eur Rev Med Pharmacol Sci. 2016; 20(10): 1986–1992.
- Mardas M, Stelmach-Mardas M, Madry R. Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival. Support Care Cancer. 2017; 25(3): 795–800.
- Hess LM, Barakat R, Tian C, et al. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2007; 107(2): 260–265.
![](https://journals.viamedica.pl/plugins/generic/popups/images/icons/close.png)